FDA Must Take Action On Omnitrope Review, Court Says; Will Plan B Follow?
This article was originally published in The Tan Sheet
Executive Summary
The case against FDA over the Plan B switch review delay will likely benefit from the precedent of a D.C. federal court ruling April 10 upholding PDUFA review deadlines as mandatory
You may also be interested in...
FDA Topsiders Must Testify In Plan B Case – Judge
The Center for Reproductive Rights will be allowed to take depositions from certain FDA "senior decision-makers" in their suit against the agency over decisions related to emergency contraceptive Plan B
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands